Researchers in this study wanted to identify new treatment strategies for triple-negative breast cancer (TNBC), an aggressive form of breast cancer that lacks the hormone receptors targeted by many standard therapies. Because TNBC often develops resistance to treatment, researchers investigated whether simultaneously targeting two important cancer-promoting pathways—the PI3K pathway and the Wnt pathway—could more effectively slow tumor growth.
To investigate this, the researchers studied TNBC cells in laboratory experiments and animal models. They treated cancer cells with drugs that inhibited either the PI3K pathway, the Wnt pathway, or both pathways together. The researchers then evaluated how these treatments affected cancer cell growth, survival, and tumor progression.
The researchers found that blocking both pathways at the same time was more effective than targeting either pathway alone. The combined treatment significantly reduced cancer cell growth, increased cancer cell death, and slowed tumor progression. The two therapies worked together synergistically, meaning their combined effect was greater than the sum of their individual effects. The findings suggest that TNBC cells rely on both pathways for survival and that dual inhibition may overcome some of the limitations of single-drug treatments.
Overall, the study demonstrates that targeting multiple cancer-promoting pathways simultaneously may be a promising strategy for treating triple-negative breast cancer.
